(24/7 MARKET NEWS) – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced, this morning, that hamsters infected with SARS-COV-2 and then treated with BiondVax’s inhaled anti-COVID-19 nanosized antibodies (NanoAbs) had over 30-times lower lung viral titer on average compared to those treated with inhaled placebo.
It’s trading higher this morning, at $3.35, up $0.186 (+5.88%), on 2.3 million shares traded.
Its 52-week range is $2.80 to $22.90. Its next key inflection point is $4.85.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.